Programming Note: John Blank was on CNBC's Closing Bell this afternoon discussing new Fed Chair Jerome Powell and the importance of the "neutral rate". Click here to watch the segment. Stocks survived another rough session for technology on Tuesday with a little help from the energy space. The major indices each closed higher, though were well short of offsetting yesterday’s pullback. The Dow advanced 0.47% to 24,727.3. The NASDAQ was much choppier but still gained 0.27% to 7364.3. The S&P increased 0.15% to 2716.9. Facebook was down another 2.5% following yesterday’s slide of nearly 7%. The social media staple is under fire for their handling of user information during the presidential campaign. Such concerns led to each of the major indices dropping by well over 1% on Monday. A more than 2% advance in oil prices helped to stabilize the market today, which was much appreciated on the eve of the Fed's rate decision. The market has no problem with a rate hike tomorrow…but it would have a BIG problem if new Fed Chair Jerome Powell gets all hawkish and hints at more than just three hikes this year. "I'll sum up the Fed as simple as I can, 4 rate hikes in 2018 is bad, 3 rate hikes is good," said Jeremy in Counterstrike. "The language coming out of the meeting will let traders know if the Fed will be hawkish or dovish for the rest of 2018. Tomorrow could really be the start of a bigger move higher of lower for the rest of the year." The portfolios did see some moves on Tuesday despite tomorrow’s uncertainty. Brian Bolan added to Technology Innovators and Stocks Under $10, while also cashing in a double-digit winner from TI. Meanwhile, Healthcare Innovators added a stock from the CRISPR field, which Kevin says is “still in its early gold-rush days”. Read more in the highlights section below. Today's Portfolio Highlights: Technology Innovators: Shares of Mulesoft (MULE) soared more than 25% today on news that Salesforce was looking to buy the company. Despite this runup, Brian Bolan added the stock on Tuesday because he believes this deal will get done quickly and at a higher price. Meanwhile, the editor also sold First Solar (FSLR) today for a 17.8% return in a little over four months. Read the full write-up for more on all of today’s moves. Healthcare Innovators: As fears of competition from a new scientific platform emerged last week, CRISPR Therapeutics (CRSP) shares dropped 10%. But, large investors are not fleeing the stock and the editor decided to buy today before the market cap takes off again. Kevin warns that this is a fairly risky play after a dramatic runup this year, and any negative industry news could drop the shares back into the $40s. But he sees the Swiss innovator, with R&D labs in Cambridge, MA, as the leading gene editing candidate for new partnerships with big bio-pharma companies as they develop their own new platform in CAR-T immuno-therapy. Learn a lot more about this new addition in the complete commentary. Stocks Under $10: Quite recently, Brian Bolan felt that Noodles & Company (NDLS) wasn’t long for this world. But times have changed. The fast casual restaurant company recently reported a penny profit rather than a penny loss, accounting for a surprise of 200%. It also has a Zacks Style Score of “A” for Growth. However, the editor was most impressed by a “glowing” review of NDLS from a well-respected analyst in the quick service restaurant space. Brian now thinks that there’s a good chance this stock eventually returns to $15. In addition to all this, the position should add a nice layer of diversification to the portfolio. Read the full write up for more on this new buy. Blockchain Innovators: "A tepid recovery today as stocks didn’t have much conviction at all. Chop was the word of the day as the major market averages all did a lot of bouncing around. "The good news is that for the most part that chop finished on a positive note. Save for the small caps of the Russell where the market dipped a toe into negative territory. "Still, the main event for the week lingers tomorrow. It’s all about the dot plot tomorrow. Tomorrow we are all mice, hoping the hawks stay home." -- Dave Bartosiak, who is also editor of Surprise Trader and Momentum Trader. Options Trader: "In addition to the expected rate rise, traders will be watching the FOMC Forecast where they’ll give their assessment on the economy and all that entails, along with hints as to the timing of their next move on interest rates. "And lastly, but surely not least, the market will be watching the language they use in these reports to see how it deviates from their prior language. And we’ll all be listening to the Fed Chair’s Press Conference. This one will take on extra importance given this will be the new Fed Chairman’s (Jerome Powell), first Press Conference after replacing Janet Yellen earlier this year. "Assuming there are no surprises, I believe this will have a longer-term bullish effect on the market as it should show the Fed’s confidence in the economy, but at the same time confirm that they will take a slow and measured pace when raising rates. "Expecting to put this correction/consolidation behind us shortly thereafter and begin a whole new leg higher." -- Kevin Matras All the Best, Jim Giaquinto Recommendations from Zacks' Private Portfolios: Believe it or not, this article is not available on the Zacks.com website. The commentary is a partial overview of the daily activity from Zacks' private recommendation services. If you would like to follow our Buy and Sell signals in real time, we've made a special arrangement for readers of this website. Starting today you can see all the recommendations from all of Zacks' portfolios absolutely free for 7 days. Our services cover everything from value stocks and momentum trades to insider buying and positive earnings surprises (which we've predicted with an astonishing 80%+ accuracy). Click here to "test drive" Zacks Ultimate for FREE >> Zacks Investment Research